Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologySarcomasDiseaseGastrointestinal Stroma TumorSubgroupKIT-Exon 9-MutationPDGFRA D842V mutationICD10C15.-C16.-C17.-C18.-C48.-MeSHGastrointestinal Stromal TumorsSequenceIMAT400/BINI30, GIST, C1 (PID2009) -|- C2+ (PID2010)ChemotherapyChemo-substanceAvapritinibBinimetinibImatinibRegorafenibRipretinibSunitinibChemo-substanceAvapritinibBinimetinibImatinibRegorafenibRipretinibSunitinibChemo-substanceAvapritinibBinimetinibImatinibRegorafenibRipretinibSunitinibChemo-substanceAvapritinibBinimetinibImatinibRegorafenibRipretinibSunitinibNo. Substances12 RadiotherapySupportive therapySupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronNo. Substances2Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleThird line Therapy phaseTherapy intentioncurativepalliativeRisksAlopeciaAnemia Hb below 8g/dlArthalgiaAstheniaCardiotoxicityCNS ToxicityConstipationDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueHand-Foot SyndromeHemorrhageHyperbilirubinemiaHyperkalemiaHypertensionHypertriglyceridemiaHypokalemiaHyponatremiaHypophosphatemiaHypothyroidismIncrease AminotransferasesIncrease Creatinine PhosphokinaseMucositisMyalgiasNauseaNeutropeniaOral MucositisPleural EffusionPruritusRashSeizuresThrombocytopenia below 50 000/µl only studiesPublicationAuthorBlay JYChi PDemetri GHeinrich MCJoensuu HVan Glabbeke MDiseasefortgeschrittener, nicht operabler gastrointestinaler Stromatumor, Zweitlinie nach Imatinib, ECOG 0-1fortgeschrittener gastrointestinaler Stromatumor, Erstlinie oder Imatinib adjuvant, ECOG 0-1gastrointestinaler Stromatumor, adjuvantGastrointestinaler Stromatumor, inoperabel, PDGFRA D842V-mutiert, ECOG 0-2metastasierter, inoperabler gastrointestinaler Stromatumor nach Imatinib und Sunitinib, ECOG 0-1Nichtresezierbarer oder metastasierter gastrointestinaler Stromatumornichtresezierbarer oder metastasierter gastrointestinaler Stromatumor, CD117 expressionierend, ECOG < 3nichtresezierbarer oder metastasierter GIST, nach Therapie mit 3 oder mehr Kinase-Hemmern, einschließlich Imatinib, Sunitinib und RegorafenibOriginCentre Leon Berard, Lyon, France, INVICTUS trialDepartment of Oncology, Helsinki University Central Hospital, FinnlandFrom the Dana–Farber Cancer Institute and Harvard Cancer Center, BostonGastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New YorkKnight Cancer Institute, Portland, USA, NAVIGATOR trialLudwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, USALudwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA, GRID trialProtocols in Revision 9 protocols foundAvapritinib 300, Gastrointestinal Stroma Tumor (PID1689 V1.1)Imatinib 400 / Binimetinib 30, Gastrointestinal Stromal Tumor, cycle 1 (PID2009 V1.0)Imatinib 400 / Binimetinib 30, Gastrointestinal Stromal Tumor, cycle 2+ (PID2010 V1.0)Imatinib 400, Gastrointestinal Stroma Tumor (PID796 V1.1)Imatinib 400, Gastrointestinal Stroma Tumor, adjuvant (PID569 V1.1)Imatinib 400, Gastrointestinal Stroma Tumor, Variant 1 (PID3158 V1.0)Regorafenib 160, Gastrointestinal Stroma Tumor (PID795 V1.0)Ripretinib 150, Gastrointestinal Stroma Tumor (PID1955 V1.0)Sunitinib 50, Gastrointestinal Stroma Tumor (PID794 V1.0)
